Mediscience forms Asian clinical research network
This article was originally published in Scrip
Executive Summary
The Japanese pharmaceutical contract research organisation Mediscience Planning has formed an alliance with two other operations in Asia to strengthen its capabilities for regional clinical development. It will work with the Taiwanese subsidiary of the US CRO PRA International and South Korea's LSK Global Pharma Services to offer customers a network for performing Asian multinational trials and accessing other contract services from the three firms. Mediscience raised around $6 million in its recent float on the Hercules exchange in Japan, and provides a range of regulatory, data management, clinical and other services (Scrip Online, October 15th, 2008).
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.